Robbins & Myers (NYSE: RBN ) reported earnings on Jan. 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Nov. 30 (Q1), Robbins & Myers missed on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly, and earnings per share grew significantly.
Margins increased across the board.
Revenue details
Robbins & Myers logged revenue of $237 million. The nine analysts polled by S&P Capital IQ looked for revenue of $243 million. Sales were 69% higher than the prior-year quarter's $164 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS details
EPS came in at $0.77. The nine earnings estimates compiled by S&P Capital IQ anticipated $0.68 per share. GAAP EPS of $0.77 for Q1 were 74% higher than the prior-year quarter's $0.44 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 40.3%, 240 basis points better than the prior-year quarter. Operating margin was 22.2%, 510 basis points better than the prior-year quarter. Net margin was 14.9%, 450 basis points better than the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods.
Looking ahead
What does the future hold?
Next quarter's average estimate for revenue is $247 million. On the bottom line, the average EPS estimate is $0.73.
Next year's average estimate for revenue is $1.0 billion. The average EPS estimate is $3.09.
Investor Sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 194 members out of 202 rating the stock outperform, and eight members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Robbins & Myers a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Robbins & Myers is buy, with an average price target of $53.67.
- Add Robbins & Myers to My Watchlist.
No comments:
Post a Comment